Genovis AB (publ.) (GENO.ST)
SEK 24.35
(2.31%)
SEK 24.35
(2.31%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -43.94 Million SEK | 32.92% |
| 2022 | -65.5 Million SEK | 16.53% |
| 2021 | -78.48 Million SEK | -109.53% |
| 2020 | -37.45 Million SEK | -263.25% |
| 2019 | -10.31 Million SEK | -133.83% |
| 2018 | -4.4 Million SEK | -56.89% |
| 2017 | -2.81 Million SEK | 32.21% |
| 2016 | -4.14 Million SEK | -121.48% |
| 2015 | -1.87 Million SEK | -304.39% |
| 2014 | -462.96 Thousand SEK | 3.63% |
| 2013 | -480.42 Thousand SEK | 92.81% |
| 2012 | -6.68 Million SEK | 8.68% |
| 2011 | -7.31 Million SEK | -100.56% |
| 2010 | -3.64 Million SEK | -5816.01% |
| 2009 | 63.84 Thousand SEK | -98.17% |
| 2008 | 3.48 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -58.29 Million SEK | -0.09% |
| 2024 Q1 | -58.24 Million SEK | -32.56% |
| 2023 Q2 | -108.48 Million SEK | 0.47% |
| 2023 Q1 | -108.99 Million SEK | -66.39% |
| 2023 Q3 | -38.54 Million SEK | 64.47% |
| 2023 FY | -43.94 Million SEK | 32.92% |
| 2023 Q4 | -43.94 Million SEK | -13.99% |
| 2022 Q3 | -70.8 Million SEK | 0.77% |
| 2022 FY | -65.5 Million SEK | 16.53% |
| 2022 Q1 | -71.63 Million SEK | 8.72% |
| 2022 Q2 | -71.35 Million SEK | 0.4% |
| 2022 Q4 | -65.5 Million SEK | 7.49% |
| 2021 Q3 | -41.32 Million SEK | -11.06% |
| 2021 Q4 | -78.48 Million SEK | -89.94% |
| 2021 Q2 | -37.2 Million SEK | 15.04% |
| 2021 FY | -78.48 Million SEK | -109.53% |
| 2021 Q1 | -43.79 Million SEK | -16.92% |
| 2020 Q2 | -43.15 Million SEK | 27.66% |
| 2020 FY | -37.45 Million SEK | -263.25% |
| 2020 Q3 | -43.38 Million SEK | -0.53% |
| 2020 Q4 | -37.45 Million SEK | 13.67% |
| 2020 Q1 | -59.65 Million SEK | -478.57% |
| 2019 Q3 | -10.62 Million SEK | -77.6% |
| 2019 Q4 | -10.31 Million SEK | 2.92% |
| 2019 Q2 | -5.98 Million SEK | 26.02% |
| 2019 FY | -10.31 Million SEK | -133.83% |
| 2019 Q1 | -8.08 Million SEK | -83.34% |
| 2018 Q4 | -4.4 Million SEK | -58.69% |
| 2018 Q2 | -599 Thousand SEK | -110.5% |
| 2018 Q1 | 5.7 Million SEK | 302.97% |
| 2018 FY | -4.4 Million SEK | -56.89% |
| 2018 Q3 | -2.77 Million SEK | -363.94% |
| 2017 FY | -2.81 Million SEK | 32.21% |
| 2017 Q4 | -2.81 Million SEK | 56.69% |
| 2017 Q2 | -8.19 Million SEK | -353.96% |
| 2017 Q1 | -1.8 Million SEK | 56.47% |
| 2017 Q3 | -6.49 Million SEK | 20.8% |
| 2016 Q4 | -4.14 Million SEK | 35.85% |
| 2016 FY | -4.14 Million SEK | -121.48% |
| 2016 Q2 | -9.87 Million SEK | -208.91% |
| 2016 Q3 | -6.46 Million SEK | 34.55% |
| 2016 Q1 | -3.19 Million SEK | -70.76% |
| 2015 Q3 | -5.96 Million SEK | 34.16% |
| 2015 Q1 | -1.54 Million SEK | -233.5% |
| 2015 Q2 | -9.06 Million SEK | -486.79% |
| 2015 FY | -1.87 Million SEK | -304.39% |
| 2015 Q4 | -1.87 Million SEK | 68.61% |
| 2014 Q1 | -5.08 Million SEK | -957.39% |
| 2014 Q3 | -7 Million SEK | -61.77% |
| 2014 Q4 | -462.96 Thousand SEK | 93.39% |
| 2014 FY | -462.96 Thousand SEK | 3.63% |
| 2014 Q2 | -4.32 Million SEK | 14.78% |
| 2013 Q4 | -480.42 Thousand SEK | 89.25% |
| 2013 Q2 | -10.85 Million SEK | -603.24% |
| 2013 Q1 | -1.54 Million SEK | 76.91% |
| 2013 FY | -480.42 Thousand SEK | 92.81% |
| 2013 Q3 | -4.47 Million SEK | 58.81% |
| 2012 FY | -6.68 Million SEK | 8.68% |
| 2012 Q2 | -14.77 Million SEK | -273.12% |
| 2012 Q3 | -10.91 Million SEK | 26.09% |
| 2012 Q4 | -6.68 Million SEK | 38.78% |
| 2012 Q1 | -3.95 Million SEK | 45.91% |
| 2011 Q1 | -1 Million SEK | 72.38% |
| 2011 Q4 | -7.31 Million SEK | 33.68% |
| 2011 FY | -7.31 Million SEK | -100.56% |
| 2011 Q3 | -11.03 Million SEK | 22.07% |
| 2011 Q2 | -14.16 Million SEK | -1304.86% |
| 2010 Q2 | -11.86 Million SEK | -1043.97% |
| 2010 Q4 | -3.64 Million SEK | 48.78% |
| 2010 Q3 | -7.12 Million SEK | 39.94% |
| 2010 Q1 | -1.03 Million SEK | -1724.27% |
| 2010 FY | -3.64 Million SEK | -5816.01% |
| 2009 Q4 | 63.84 Thousand SEK | 0.0% |
| 2009 Q1 | -1.91 Million SEK | 0.0% |
| 2009 FY | 63.84 Thousand SEK | -98.17% |
| 2008 FY | 3.48 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | -33.2 Million SEK | -32.352% |
| Biovica International AB (publ) | -58.73 Million SEK | 25.19% |
| Cantargia AB (publ) | -139.74 Million SEK | 68.557% |
| CombiGene AB (publ) | -101.44 Million SEK | 56.683% |
| Cyxone AB (publ) | -16.67 Million SEK | -163.593% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1378.499% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -49.546% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 21.374% |
| Fluicell AB (publ) | -2.76 Million SEK | -1490.337% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 86.647% |
| Mendus AB (publ) | -96.29 Million SEK | 54.368% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 68.193% |
| I-Tech AB | -83.26 Million SEK | 47.226% |
| Intervacc AB (publ) | -88.16 Million SEK | 50.158% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -37.63% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 182.56% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -130.54% |
| OncoZenge AB (publ) | -12.62 Million SEK | -247.992% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 12.002% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 126.458% |
| Lipum AB (publ) | -8.46 Million SEK | -419.09% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 12.155% |
| Ziccum AB (publ) | -2.13 Million SEK | -1956.2% |
| BioArctic AB (publ) | -606.58 Million SEK | 92.756% |
| Camurus AB (publ) | -1.16 Billion SEK | 96.229% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 47.529% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -11.576% |
| Aptahem AB (publ) | 2.9 Million SEK | 1610.705% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 86.829% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 66.067% |
| Kancera AB (publ) | -45.69 Million SEK | 3.832% |
| Saniona AB (publ) | 40.44 Million SEK | 208.638% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 2.822% |
| AcouSort AB (publ) | -23.98 Million SEK | -83.194% |
| Xintela AB (publ) | -7.8 Million SEK | -462.697% |
| Abliva AB (publ) | -57.24 Million SEK | 23.234% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 46.545% |
| Amniotics AB (publ) | -5.63 Million SEK | -680.202% |
| 2cureX AB (publ) | -13.4 Million SEK | -227.845% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -1933.364% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 913.722% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 132.619% |
| Biosergen AB | -1.88 Million SEK | -2233.563% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 314.242% |
| Corline Biomedical AB | -17.01 Million SEK | -158.294% |
| NextCell Pharma AB | -46.79 Million SEK | 6.09% |
| Nanologica AB (publ) | -9.38 Million SEK | -368.055% |
| LIDDS AB (publ) | -13.51 Million SEK | -225.2% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 77.431% |
| BioInvent International AB (publ) | -236.3 Million SEK | 81.405% |
| SynAct Pharma AB | -61.75 Million SEK | 28.85% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -105.188% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -232.152% |
| Alzinova AB (publ) | -21.22 Million SEK | -107.015% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -111.326% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 34.338% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -748.131% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 47.527% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -4660.672% |
| Simris Alg AB (publ) | 85.07 Million SEK | 151.65% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 46.47% |